Drug Profile
Factor VIII/von Willebrand factor - Grifols
Alternative Names: Alphanate; Fanhdi; Von Willebrand factor/Factor VIIILatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Talecris Biotherapeutics
- Developer Grifols
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Haemophilia A; Von Willebrand disease
Most Recent Events
- 29 Jul 2016 Grifols initiates a phase II trial for Haemophilia A (In neonates, In infants, In children) in Spain (IV) (EudraCT2015-005524-26)
- 23 Nov 2013 Grifols initiates enrolment in a phase IV postmarketing study for Von Willebrand's Disease (in paediatric patients with type I, II or III disease) in Spain (EudraCT2012-003450-92)
- 14 Jan 2013 Launched for Haemophilia A in USA before January 2013 (IV)